Skip to content

Opus Genetics IRD Proceeds from issuance of preferred stock

Proceeds from issuance of preferred stock at other companies

Precigen logo
PrecigenPGEN
-$134.25K-101%

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's proceeds from issuance of preferred stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's proceeds from issuance of preferred stock?
Opus Genetics (IRD) reported proceeds from issuance of preferred stock of $25M in Q1 2026.
What does proceeds from issuance of preferred stock mean?
Cash received from issuing preferred stock — hybrid equity that provides fixed dividends without common stock dilution.